Microbix Presenting at Florida Capital Event Conference
17 November 2023 - 11:00PM
Microbix Biosystems Inc. (
TSX: MBX, OTCQX: MBXBF,
Microbix®), a life sciences innovator, manufacturer, and
exporter, announces that it will be presenting to investors at the
Florida Capital Event Conference, organized by Capital Event
Management Ltd. and being hosted at the JW Marriott Turnberry, in
Aventura, Florida, November 17 to 19, 2023.
Microbix’s CEO & President, Cameron Groome,
will undertake a series of 18 one-on-one meetings with growth
company investors during the formal portion of the conference. The
presentation slides to which he will be speaking will be posted to
the Microbix website at https://microbix.com, along with other
business information and financial disclosures.
Shareholders may also join a webinar reviewing
announced progress on Kinlytic® and overall operations. This
webinar is being hosted by Adelaide Capital at 10:00 AM ET on
Friday, November 17, 2023. Participants can register here:
https://us02web.zoom.us/webinar/register/WN_ssbGvk0gT9arZNyp6BkHcQ.
The webinar will also be live-streamed and a
replay will be posted on Adelaide Capital’s YouTube Channel here:
https://www.youtube.com/channel/UC7Jpt_DWjF1qSCzfKlpLMWw.
About Microbix
BiosystemsMicrobix creates proprietary biological products
for human health, with over 100 skilled employees and annualized
sales targeting C$ 2.0 million per month. It makes a wide range of
critical ingredients and devices for the global diagnostics
industry, notably antigens for immunoassays and its laboratory
quality assessment products (QAPs™ IVD or RUO test-controls) that
support clinical lab proficiency testing, enable assay development
and validation, or help ensure the quality of clinical lab and
point-of-care diagnostic workflows. Microbix antigens enable the
antibody tests of approximately 100 diagnostics makers, while QAPs
are sold to clinical lab accreditation organizations, diagnostics
companies, and clinical labs. Microbix QAPs are now available in
over 30 countries, supported by a network of international
distributors. Microbix is ISO 9001 and 13485 accredited, U.S. FDA
registered, Australian TGA registered, Health Canada establishment
licensed, and provides CE marked products.
Microbix also applies its biological expertise
and infrastructure to develop other proprietary products and
technologies, most notably Kinlytic® urokinase, a biologic drug
used to dissolve blood clots, and viral transport medium (DxTM™)
used to stabilize patient samples for lab-based molecular
diagnostic testing. Microbix is traded on the TSX and OTCQX, and
headquartered in Mississauga, Ontario, Canada.
About Capital Event Management Ltd. and
the EventCapital Event Management Ltd. produces multiple
investor events each year, across North America, on Bermuda, and in
the Bahamas. Attendees include leading public and private
companies, and a range of investors consisting of investment
advisors, fund managers, and high net worth investors. Capital
Event’s unique event formats aim to allow principals to establish
new and lasting relationships that lead to financings, open market
support, and increased awareness within the investment community.
Further information about the Florida event is available at
https://cem.ca/conference/florida-capital-event-2023/
Forward-Looking InformationThis
news release includes “forward-looking information,” as such term
is defined in applicable securities laws. Forward-looking
information includes, without limitation, discussion of Capital
Event Management Ltd. and its conferences, Microbix’s business and
business results, goals or outlook, risks associated with financial
results and stability, development projects such as those
referenced in its corporate presentation or verbal comments, sales
to foreign jurisdictions, engineering and construction, production
(including control over costs, quality, quantity and timeliness of
delivery), foreign currency and exchange rates, maintaining
profitability and adequate working capital, or raising further
capital on acceptable terms or at all, and other similar statements
concerning anticipated future events, conditions or results that
are not historical facts. These statements reflect management’s
current estimates, beliefs, intentions and expectations; they are
not guarantees of future performance. The Company cautions that all
forward looking information is inherently uncertain, and that
actual performance may be affected by many material factors, some
of which are beyond the Company’s control. Accordingly, actual
future events, conditions, and results may differ materially from
the estimates, beliefs, intentions, and expectations expressed or
implied in the forward-looking information. All statements are made
as of the date of this news release and represent the Company’s
judgement as of the date of this new release, and the Company is
under no obligation to update or alter any forward-looking
information.
Please visit www.microbix.com or
www.sedar.com for recent Microbix news and filings.
For further information, please contact Microbix
at:
Cameron Groome, CEO(905) 361-8910 |
Jim Currie, CFO(905) 361-8910 |
Deborah Honig, Investor RelationsAdelaide Capital Markets(647)
203-8793 ir@microbix.com |
Copyright © 2023 Microbix Biosystems Inc.
Microbix®, DxTM™, Kinlytic®, and QAPs™ are trademarks of Microbix
Biosystems Inc.
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Jul 2023 to Jul 2024